Cargando…

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer

BACKGROUND: c-Met and EGFR receptors are widely expressed on cancer cells; they are implicated in the development and progression of cancer through a plethora of effects on cell cycle progression, apoptosis, motility and metastasis and are potential targets for combination therapy. EGFR receptor tyr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puri, Neelu, Salgia, Ravi
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669728/ https://www.ncbi.nlm.nih.gov/pubmed/19240370 http://dx.doi.org/10.4103/1477-3163.44372

Ejemplares similares

Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer
por: Fong, Jason T., et al.
Publicado: (2013)

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Botting, Gregory M., et al.
Publicado: (2015)

EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer
por: Crees, Zachary D, et al.
Publicado: (2020)

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
por: Ma, P C, et al.
Publicado: (2007)

Modulating the Effect of β-Sitosterol Conjugated with Magnetic Nanocarriers to Inhibit EGFR and Met Receptor Cross Talk
por: Ilangovan, Shanmuga Sundari, et al.
Publicado: (2023)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
por: Tan, Yi-Hung Carol, et al.
Publicado: (2017)

Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice
por: Stabile, Laura P., et al.
Publicado: (2010)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)

Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer
por: Praveen, Paurush, et al.
Publicado: (2016)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2010)

Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth
por: Balan, Murugabaskar, et al.
Publicado: (2017)

Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors
por: Salgia, Ravi
Publicado: (2014)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report
por: Roth, Katherine G., et al.
Publicado: (2020)

The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met(+) Hepatocellular Carcinoma
por: Steinway, Steven N., et al.
Publicado: (2015)

Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment
por: Wong, Sze‐Ching, et al.
Publicado: (2023)

Cigarette smoke enhances oncogene addiction to c‐MET and desensitizes EGFR‐expressing non‐small cell lung cancer to EGFR TKIs
por: Tu, Chih‐Yen, et al.
Publicado: (2018)

Correction: CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2011)

MET/PKCß expression correlate with metastasis and inhibition is synergistic in lung cancer
por: Faoro, Leonardo, et al.
Publicado: (2009)

The Cross-Talk Between EGFR and E-Cadherin
por: Ramírez Moreno, Miguel, et al.
Publicado: (2022)

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
por: Kanteti, Rajani, et al.
Publicado: (2014)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
por: Liu, Li, et al.
Publicado: (2021)

Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis
por: Shieh, Jiunn-Min, et al.
Publicado: (2013)

Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway
por: Xu, Zhong, et al.
Publicado: (2018)

Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity
por: Mhone, Thomas Gabriel, et al.
Publicado: (2022)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
por: Taniguchi, Hirokazu, et al.
Publicado: (2017)

Deoxypodophyllotoxin Inhibits Cell Growth and Induces Apoptosis by Blocking EGFR and MET in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Kim, Han Sol, et al.
Publicado: (2021)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Combined Checkpoint Inhibition and Chemotherapy: New Era of 1(st)-Line Treatment for Non-Small-Cell Lung Cancer
por: Wang, Chongkai, et al.
Publicado: (2019)

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
por: Ju, Lixia, et al.
Publicado: (2013)

Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
por: Gao, Hong-Fei, et al.
Publicado: (2016)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

Wnt Signaling Cross-Talks with JH Signaling by Suppressing Met and gce Expression
por: Abdou, Mohamed, et al.
Publicado: (2011)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
por: Wu, D-W, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_95tk4t8ava2f0lc040dh664cvp